摘要 |
Solid formulations of indolinones are disclosed, wherein the formulations comprise 15-40 % w/w of an indolinone of formula (I), 10-86 % w/w of one or more pharmaceutically acceptable diluents, 2-20 % w/w of one or more pharmaceutically acceptable binders, 2-20 % w/w of one or more pharmaceutically acceptable disintegrants, and1-10 % w/w of one or more pharmaceutically acceptable lubricants, wherein the variables shown in formula (I) are as defined in the specification. These solid formulations are suitable for parenteral or oral administration. The formulations and the compounds themselves are useful for the treatment of protein kinase related disorders. In one embodiment the solid formulation comprises 40 % w/w of an indolinone of formula (I), or a pharmaceutically acceptable salt thereof, 47.5 % w/w mannitol, 6 % w/w croscaramellose sodium, 5 % w/w povidone and 1.5 % w/w magnesium stearate.
|